NASDAQ · ATEC

Alphatec Holdings, Inc.

$8.67 +$0.41 (+4.96%) 1D After hours

Key Metrics

$1.27B
Market cap
P/E · TTM
Revenue · TTM
−$125.36M
Net income
EPS · TTM $-0.85
Dividend yield
Free cash flow $6.95M
Beta · 1Y 0.51
EBITDA · TTM −$48.57M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 7
    The stock moved +10.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7
  • May 6
    From its Jan 30 high, the share price fell 53%.

    Peak close $14.83 on Jan 30; trough close $6.99 on May 6. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -53%
  • May 6
    The stock moved -31.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.27B
Enterprise value$1.70B
Shares outstanding153.8M
52-wk range$6.82 – $23.29
Avg volume · 20D1.5M
Net cash −$433.50M
Book value / share$-0.04
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Alphatec Holdings, Inc.
IPO dateJun 2, 2006
Employees913

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF182.80
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 1,284.7% · -29.3%

Financial Health

Current ratio1.90
Quick ratio1.12
Debt / equity-107.24
Debt / EBITDA -11.81
Net cash −$433.50M
Working capital$215.92M

Cash Flow · TTM

Operating CF $51.56M
Capex −$44.61M
Free cash flow $6.95M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings